The mainstay of treatment for cancer is surgical resection. However, surgery itself has the potential to promote the development of metastases and reduce subsequent survival. Surgery can promote metastatic disease due to inappropriate tumour handling leading to seeding, removing inhibition of residual disease by removal of the primary tumour, release of growth factors such as vascular endothelial growth factor, and, perhaps most importantly, immunosuppression. 1 Major surgery is known to suppress cell-mediated immunity, in particular natural killer cells, which are important during the peri-and postoperative period in reducing micrometastatic formation. 2 There has been recent interest in the effect postoperative analgesia may have on disease recurrence and survival after cancer surgery. 3 -8 Postoperative pain relief usually involves a choice of either regional analgesia or systemic opioids, usually morphine. Morphine can produce immunosuppression by inhibiting components of the immune system such as a reduction in natural killer cell activity and altering cytokine expression. 9 Regional analgesia (spinal or epidural) causes a sympathetic block, which is thought to attenuate the neuroendocrine stress response and preserve cellular immunity.
with the use of regional analgesia. A randomized study for colon cancer has also identified an enhanced survival with the use of epidural analgesia but only up to 1.46 yr postsurgery. 6 However, two other retrospective series have identified no benefit with epidural analgesia for cancer recurrence after major abdominal cancer surgery 5 and colorectal cancer surgery.
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As the current evidence is limited and conflicting, we have performed a retrospective analysis of patients undergoing laparoscopic colorectal surgery for bowel cancer. We hypothesized that regional analgesia (epidural and spinal) would provide a survival advantage in colorectal cancer resection over morphine-based patient-controlled analgesia (PCA).
Methods
A retrospective study of all patients undergoing laparoscopic colorectal resections for bowel cancer between October 2003 and December 2010 was performed. Necessary data were gathered from a prospectively kept database, the patient's clinical records, electronic patient records, and by contacting the primary care doctor as appropriate.
The treatment plan for patients was decided by consensus opinion at the local multidisciplinary team (MDT) meeting, where appropriate imaging, histology, and patient history were reviewed. Laparoscopic resections were either performed or supervised by two consultant laparoscopic colorectal surgeons in one hospital. The dissection was in a standard medial to lateral approach, with early division of the vessels. The specimen was extracted through an incision in the abdominal wall, protected by a wound protector, just large enough to allow specimen extraction. If an incision was made larger than that required for specimen extraction, this was considered a conversion. If chemotherapy was considered appropriate by the MDT, this was administered locally.
The primary postoperative analgesia was determined either by the anaesthetist, patient preference, or by randomization if enrolled in a trial. During the time period analysed, two randomized trials were conducted: NCT18926278 and NCT01128088. Ethical approval was given for these trials from the local ethics committee. Epidural analgesia involved placement of a catheter between T9 and T12, with a bolus of 10 ml bupivacaine 0.2% with fentanyl 100 mg. An infusion of bupivacaine 0.15% with fentanyl 0.0002% was then commenced at 4-8 ml h 21 as tolerated throughout surgery and for the first 48 h after operation. Spinal analgesia involved insertion of 2.5 ml hyperbaric bupivacaine 0.5% with diamorphine 0.25 mg at the L2 -3 or L3-4 interspace with the patient sitting before induction. Patients receiving PCA were given morphine 10 mg during surgery and then a PCA set to deliver a 1 mg bolus on demand with a maximum of 20 mg every 4 h. In addition, it is the standard practice within the hospital for patients to receive intraoperative goal-directed fluid administration with oesophageal Doppler monitoring. Patients would not routinely receive dexamethasone. Survival and recurrence were calculated from the time of operation to event. The data were analysed using PASW Statistics Version 18.0. Patient variables were analysed using appropriate statistical tests. These were one-way ANOVA, Pearson's x 2 test, an independent samples Kruskal-Wallis test, and an independent samples median test. Survival analysis was performed using the Kaplan-Meier survival function with a log-rank test to assess significance. Statistical significance was taken as a value of P,0.05.
Results
During the time period analysed, there were a total of 457 elective laparoscopic colorectal resections performed for colorectal adenocarcinoma. Of these, 33 were excluded from analysis because they received oral analgesia only (6), i.v. morphine not by PCA (19), and information was missing (8) . This left 424 cases suitable for analysis: epidural (107), spinal (144), and PCA (173) (Fig. 1) . The various analgesia methods were not distributed evenly over the time period analysed (Table 1) . This reflects the median follow-up times of 37 months for the epidural group, 28 months for the PCA group, and 17 months for the spinal group.
There was no significant difference between the three groups for age, gender, or rate of conversion (P¼0.229) ( Table 2 ). There was a significant difference in the distribution of ASA classification between the groups (P¼0.006); the epidural group had a greater proportion of ASA category III patients. The median length of stay was significantly longer in the epidural group at 5 days compared with the spinal and PCA groups at 3 days (P,0.0005). While there was no significant difference in the distribution of operations performed, the epidural group does have the largest number of abdomino-perineal resections (Table 3) . If patients receiving a stoma (defunctioning or end) are excluded, there is still a significantly longer length of stay (P¼0.0005) in the epidural group (4 days) compared with the spinal (3 days) and PCA (3 days) groups. There were no differences in major complications or the percentage of patients receiving a postoperative blood transfusion (Supplementary Table S1 ).
There was no significant difference identified between the three groups for T stage (P¼0. Tables  S2 and S3 ).
There was no significant difference detected between the three groups in overall survival for all patients (P¼0.622) (Fig. 2) . The 5 yr overall survival after laparoscopic colorectal resection for epidural, spinal, and PCA groups was 69.4%, 78.2%, and 77%, respectively. If the extranodal metastatic patients are excluded and only those with Dukes A, B, or C pathology are analysed, there is still no significant difference between the three groups for overall survival (P¼0.284). The 5 yr overall survival after laparoscopic colorectal resection for Dukes A, B or C patients for epidural, spinal, and PCA groups was 75.8%, 78.2%, and 82.8%, respectively. In addition, there was no significant difference detected in disease-free survival for the three groups (P¼0.490) (Fig. 3) . The 5 yr diseasefree survival after laparoscopic colorectal resection for Analysis of the effect of postoperative analgesia on survival epidural, spinal, and PCA groups was 72%, 76%, and 72%, respectively. In order to allow for potential confounding effects of various covariates, a Cox's regression analysis was performed, including all statistically significant covariates. The covariates gender, T stage, and ASA classification were not significant. The following covariates were significant: N stage (P,0.0005), M stage (,0.0005), transfusion (P¼0.017), conversion (P¼0.006), and age (P¼0.008). Using all significant covariates in the Cox regression analysis along with the three analgesia methods studied, no significant difference in survival was found between the three groups (P¼0.75).
Discussion
While surgical resection is essential in the treatment of colorectal cancer, it is a potential double-edged sword. The immunosuppression that accompanies surgery in the periand postoperative period may have an effect on disease recurrence and subsequent survival. Suppression of cellular immunity, and reduced natural killer cell numbers and function, may allow micrometastatic spread. 2 Any action that can attenuate this effect would be extremely valuable. Initial research into regional analgesia has focused on the short-term benefits that can be achieved with its use in open colorectal surgery. 12 Epidural analgesia has been shown to reduce the stress response and preserve natural killer cell cytotoxicity in open colectomy. 13 In addition, running the epidural during surgery and after operation can further attenuate immunosupression. 4 If regional analgesia techniques are not used, then opioid-based analgesia (usually morphine) is used. This in itself can produce immunosuppression by reducing natural killer cells and altering the balance of cytokines. 9 Work performed on mice and rats looking at postoperative immune function and metastatic formation showed that compared with general anaesthesia alone, a spinal block for a laparotomy attenuated lung tumour development after inoculation.
14 Interestingly, there was no attenuation in the reduction in natural killer cells. A greater reduction in the formation of metastases after laparotomy in mice when accompanied by a spinal block has also been shown. 15 There have been some retrospective studies conducted looking at the effect regional analgesia may have on disease recurrence and survival in different cancers. A 57% lower risk of recurrence, using prostate-specific antigen as a marker of biochemical recurrence, has been shown with epidural analgesia compared with morphine analgesia after open radical prostatectomy surgery. 7 This study was not randomized and the epidural group had a greater number of clear margins on resection, but not reaching significance (P¼0.06). A comparison of disease recurrence in patients undergoing breast cancer surgery given paravertebral or morphine analgesia identified a recurrence-free survival of 94% with paravertebral compared with 77% with morphine analgesia at 3 yr (P¼0.012). 8 There have been two retrospective studies looking at the effect of epidural analgesia compared with morphine analgesia on recurrence and survival after colorectal cancer surgery. No decrease in cancer recurrence was found for epidural analgesia, except for a potential benefit in older patients. 11 A significant reduction in all-cause mortality was found after rectal cancer resection with epidural usage, but not in colonic cancer. 3 Caution must be taken as the number in the rectal group receiving morphine PCA (n¼35) was small in comparison with the epidural group (n¼260). We looked at our subgroup with rectal cancer and found no difference in overall survival (P¼0.749) between the three groups: epidural (n¼44), spinal (n¼30), and PCA (n¼36). Two further studies have been published which have drawn data from randomized trials looking at short-term outcomes for epidural analgesia. 5 6 One identified an enhanced survival in patients with non-metastatic colon cancer receiving epidural analgesia, but only up to 1.46 yr. 6 Thereafter, no advantage was seen with epidural analgesia for long-term survival. The other showed no difference in recurrence-free survival with the use of epidural analgesia in patients undergoing major abdominal cancer surgery.
5
While this study incorporated a number of different tumour types, there were sufficient numbers to allow a subgroup analysis of those patients with colon cancer. No advantage was identified with the use of epidural analgesia. Our retrospective study, with a reasonable cohort of patients, has identified no overall or disease-free survival advantage with the use of regional analgesia (spinal or epidural) in patients undergoing laparoscopic colorectal cancer resection. No survival advantage was seen with regional analgesia even when patients with extranodal metastases were removed from the analysis. There are obvious limitations to this study due to the retrospective nature in which it has been conducted. Patients were not randomized, although during the time period reviewed, there have been two separate randomized controlled trials (RCTs) (NCT18926278 and NCT01128088) conducted to look at the short-term outcomes of analgesia in laparoscopic colorectal surgery. These two studies accounted for 24% of the patients in the analysis. Accurate data on the median dose of morphine (0 and 40 mg for the spinal and PCA groups, respectively) administered are available from the NCT18926278 trial, which provides a fair representation of the care of non-trial patients.
The epidural group had a greater number of ASA III patients, which may have accounted for the trend in reduced overall survival. Our epidural usage has reduced significantly in recent years (Table 1) as a result of an RCT we conducted which showed a longer length of stay with epidural analgesia compared with spinal or PCA analgesia. 16 There is evidence that blood transfusion may have an immunosuppressive effect; 2 however, in our analysis, there was no significant difference (P¼0.265) in the number of patients receiving a blood transfusion during the postoperative period. The majority of those patients who were transfused were not as a result of blood loss, but instead in an effort to optimize oxygen delivery secondary to anaemia resulting from their cancer. It is worth noting that the epidural group did have a higher rate of transfusion, this probably is a reflection of the number of co-morbidities in this group. All the studies published so far have looked at patients undergoing open surgery and not via the laparoscopic approach. Our study has looked only at those receiving laparoscopic colorectal resections. The reason we may not have identified a survival advantage with the use of regional analgesia in this study may be due to the laparoscopic approach. Laparoscopy is known to reduce the degree of immunosuppression that occurs during the postoperative period compared with that at open colorectal resection. 17 If a significant preservation of immune function occurs with laparoscopic colorectal resection, the choice of analgesia used may be less important. Our study has identified no overall or disease-free survival advantage with the use of regional analgesia in laparoscopic colorectal surgery vs the use of PCA.
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